Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Astellas Pharma Inc to form strategic partnership with ClearPath to build vaccine portfolio


Monday, 6 Jan 2014 02:00am EST 

Astellas Pharma Inc:Says strategic partnership with ClearPath Development company to form a portfolio of development companies focused on vaccines targeting infectious diseases.Says the partnership was established to support Astellas' goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in Dec. 2013.Says Astellas will fund RSVC's development of a virosome vaccine technology, licensed from Mymetics Corporation for respiratory syncytial virus (RSV) through completion of a Phase 2b human proof-of-concept study.Says based on the strategic partnership, Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product. 

Company Quote

1707.0
9.5 +0.56%
28 Nov 2014